“The stubborn constituent piece betwixt lens yellowing and time of life could support reduce to law wherefore be motionless disorders be converted into other thing common by increasing a hundred years,” reported Business Kessel, M.D., Ph.D., the study’s be the commander composer.

In the Danish study, 970 volunteers had their eyes examined through . lens autofluorometry, a non-invasive process according to determining how much blue light is transmitted into the retina. Blue light is a portion of the visible-light spectrum that influences the normal sleep cycle by helping initiate the release of melatonin in the brain. Melatonin is a hormone that helps signal to the body when it is time to be sleepy or alert.

Volunteers were considered to have a sleep disorder if they confirmed that they “often suffer from insomnia” or if they purchased prescription sleeping pills within the last 12 months. Of those classified as having a sleep disturbance, 82.8 percent affirmed that they both suffered from insomnia and used sleep medication.

Using this data, researchers calculated an inverse relationship between blue light transmission and the risk of having sleep disturbances: the lower the blue light transmission into the retina due to a yellowing of the eye lens, the greater the risk of sleep disturbances.

She said another important factor to consider is that sleep quality has been shown to improve after cataract surgery. “The transmission of blue light currently cannot be improved by any other method than cataract surgery. I´m involved with another research project where we try non-invasively to remove the yellow color of the lens using a laser, but the method is not yet developed for clinical use,” Kessel said.

Significantly higher rates of sleep disorders were reported by older participants, women, smokers and those with diabetes mellitus. Previous studies have shown that the rate of lens aging is accelerated in smokers, patients with diabetes mellitus and those at high risk for ischemic heart diseases. The Danish researchers addressed these factors in their statistical analyses.

“The association between blue light lens transmission and sleep disturbances remained significant even after we corrected for age, sex, diabetes mellitus, smoking and the risk of ischemic heart disease,” Kessel said.

“The results showed that while age-related lens yellowing is of relatively little importance for visual function, it may be responsible for insomnia in the elderly,” said Kessel, a senior scientist in the Department of Opthalmology at Glostrup Hospital in Denmark.

In the meantime, Kessel said it seemed prudent to recommend that physicians reconsider the prescription of sleeping tablets in patients who have undergone cataract surgery.

To the time when lately, excepting that obstructed sight surgeons — not their patients — weighed the risks and benefits of several IOLs. The surgeons’ discussions focused without ceasing the surgical technique (sinless cornea, microscopic cut, etc.) and the pertaining to physics design of the lenses (one-piece vs. multi-piece, acrylic vs. silicone) and in what way that design foppish insertion, positioning and restoring.

Obliging spectre subsequent to fall surgery was one more of influence significance. No more than things being so that unaccustomed IOLs be in actual possession of been introduced that clear to a greater degree illusion problems than till doomsday, obstructed sight surgeons consider to a greater degree to mark judgment choosing IOLs with respect to their patients’ of the eye indispensably. Obstructed sight patients are decorous other involved in the alternative similar to well.

Admitting that you or someone you be assured of faculty of volition subsist undergoing fall surgery, weigh your choices in the following laconic of the principally newly developed IOLs.

Recompense IOLs: Multifocal Accommodating

Orally transmitted IOLs are monofocal, intent they overture chimera at common degree of remoteness merely (very much, interposed or about to happen). They definitely are one ameliorating by the cataractous lens that is replaced for the time of surgery, that provides sole cloudy, blurred vision at any distance. But traditional IOLs mean that you must wear eyeglasses or contact lenses in order to read, use a computer or view objects at arm’s length.

The new multifocal and accommodating IOLs such as Crystalens offer the possibility of seeing well at more than one distance, without glasses or contacts. Examples of multifocal IOLs are different versions of Alcon’s AcrySof IQ ReSTOR. Abbott Medical Optics also offers the Tecnis and ReZoom multifocal lenses.

Presbyopia-correcting IOLs are considered “premium” lenses, which means that you must pay any associated extra cataract surgery costs yourself. Medicare and most health care plans will not cover these extra costs, because the additional benefits of these IOLs are considered a luxury and not a medical necessity.

Toric IOLs for Astigmatism

Toric IOLs designed to correct astigmatism also are considered “premium” lenses, and — like multifocal and accommodating IOLs — likely will cost you extra because of benefits that are unavailable in conventional IOLs.

FDA-approved in 1998, the Staar Surgical Intraocular Lens was the first toric IOL available in the United States. The Staar toric IOL comes in a full range of distance vision powers, in two versions. One corrects up to 2.00 diopters (D) of astigmatism and the other corrects up to 3.50 D.

The FDA also approved the AcrySof IQ Toric IOL (Alcon) in September 2005. Different models of this toric IOL can correct 1.50 to 3.00 D of astigmatism. This lens also is available in aspheric versions for crisper vision. Different models also can filter potentially damaging UV or blue light.

Most surgeons who treat astigmatism in their cataract patients tend to use astigmatic keratotomy (AK) or limbal relaxing incisions, which involve making incisions in the cornea.

But in addition to or even instead of corneal astigmatism, some people may have lenticular astigmatism, caused by irregularity in the shape of the natural lens inside the eye. This can be corrected with a toric IOL. Risks include poor vision due to the lens rotating out of position, with the possibility of further surgery to reposition or replace the IOL.

Monovision With Intraocular Lenses

If your cataract surgery involves both eyes, you might consider monovision. This involves implanting an IOL in one eye that provides near vision and an IOL in the other eye that provides distance vision.

The aspheric version of Alcon’s AcrySof IQ Toric IOL is an astigmatism-correcting “premium” intraocular lens.

Usually people can adjust to this. But if you can’t, your vision may be blurred at both near and far. Another problem is that depth perception may decrease because there is less binocular vision — meaning, your eyes aren’t working together as they once did.

People who do best with this method already are accustomed to monovision with contact lenses, which is a common way of correcting presbyopia. If you can’t adjust to monovision after your cataract surgery, you may wish you had tried a multifocal or accommodating IOL instead. Some surgeons will trial-fit a cataract patient in monovision contact lenses prior to inserting monovision IOLs.

As more and more people choose the new IOLs, they may become fully covered by health insurance or vision insurance some day. Check the terms of your insurance policy to be sure of the coverage you have prior to surgery.

Aspheric IOLs

Traditional IOLs are spherical, meaning the front surface is uniformly curved. Aspheric IOLs, first launched by Bausch + Lomb in 2004, are slightly flatter in the periphery and are designed to provide better contrast sensitivity. The original Bausch + Lomb offering is called the SofPort Advanced Optics IOL.

Bausch + Lomb also recently introduced the Akreos AO Aspheric IOL, and promotes this lens as having the ability to reduce visual aberrations. The Tecnis Z9000 (Abbott Medical Optics) also is advertised with this feature, which can improve ability to see in varying light conditions such as rain, snow, fog, twilight and nighttime darkness.

According to manufacturer AMO, the Tecnis IOL was designed using wavefront analysis of human corneas. Wavefront is the same tool that is used to plan personalized custom LASIK procedures to reduce higher-order aberrations in the visual system.

The Softec HD (Lenstec Inc.) is an aspheric intraocular lens (IOL) that may help reduce visual aberrations. The IOL received FDA approval in April 2010.

Aspheric IOLs also are available from Alcon, including the AcrySof SN60WF that includes the blue light-blocking feature discussed below and the aspheric version of AcrySof IQ ReSTOR.

Many aspheric IOLs have a Medicare “new technology” designation, which enables extra reimbursement to the surgeon of $50 per lens.

Some cataract surgeons have debated the benefits of aspheric IOLs, because the contrast sensitivity benefit may not last in older patients. After the period of cloudy, blurred vision that most cataract patients must endure before their surgery, improved contrast sensitivity is indeed a blessing. But since the ganglion cells of the retina are a major determinant of contrast sensitivity and we gradually lose these cells as we age, over time contrast sensitivity will decrease as well.

However, younger people are undergoing cataract surgery now, and this group is likely to have more and healthier ganglion cells. So they would be able to enjoy the better contrast sensitivity for a longer time.

Blue Light-Filtering IOLs

AcrySof Natural filters both ultraviolet (UV) and high-energy blue light, both of which are present in natural and artificially produced light. UV rays have long been suspected to cause cataracts and other vision problems, and many IOLs filter them out just as your natural crystalline lens does before its removal in cataract surgery.

Blue light, which ranges from 400 to 500 nanometers (nm) in the visible light spectrum, may cause retinal damage and play a role in the onset of age-related macular degeneration.

The AcrySof Natural is colored a transparent yellow in order to filter the blue light; actually, the color is similar to that of the natural crystalline lens, so the idea behind the AcrySof Natural is to restore the protection against blue light that is lost when the natural lens is removed. According to Alcon, the manufacturer, the yellow tint doesn’t alter the color of your environment or your vision quality.

If you have a less than optimal result from the original intraocular lens used in your cataract surgery, your eye surgeon might discuss with you the option of inserting an additional lens over the top of the one you have currently.

A study reported in the December 2010 issue of Journal of Cataract Refractive Surgery found that cataract patients with yellow-tinted IOLs had more difficulty seeing in the blue ranges of color under dim lighting conditions.

Light-Adjustable Lenses (LALs)

Already available in some countries outside the U.S., light-adjustable lenses (LALs) can be altered for better vision correction even after they have been surgically implanted. Adjustments are made through a light delivery device developed by Calhoun Vision of Pasadena, Calif.

LALs tested in a recent small Tijuana study involving 14 eyes were treated with a certain wavelength of light to alter the curvature of the lens after surgical implantation. This helped eye surgeons achieve targeted corrections within a quarter diopter in all but one of the eyes.

Light-adjustable intraocular lenses are now undergoing FDA clinical trials, and may become commercially available in the U.S. if they are proven safe and effective.

“Piggyback” IOLs

However, some studies including one based in Austria indicate that some contrast sensitivity might be lost with a blue light-filtering IOL. In the Austrian study, few people who had blue light-filtering IOLs noticed any decrease in vision quality when they were given a questionnaire — although subtle differences were noted in eye tests.

This approach, known as a “piggyback lens,” likely can improve vision and may be considered safer than removing and replacing the existing lens.

If you require extremely high degrees of vision correction, such as for severe myopia or astigmatism, your eye surgeon might advise combining the strengths of two intraocular lenses in one eye by using the “piggyback” approach.

IOL Cost and Availability

Because some of the IOLs mentioned in this article are relatively new, not all cataract surgeons are trained to implant them. So if you would like to find out whether you’re a candidate for one of these lenses, you may need to call several surgeons in your area to find out who uses them.

Ask a lot of questions. You want to be sure that the cataract surgeon you choose has plenty of experience with the lenses and is prepared to deal with any problems that could arise with your particular vision situation and eye health status.

Statistically, cataract removal/IOL implantation has one of the highest success rates among all surgeries, but it’s important to know the risks beforehand. Ask your surgeon to explain any potential problems that your new IOLs could cause. For example, some IOLs have been associated with a higher rate of posterior capsule opacification — that is, clouding of a membrane that is purposely left in the eye at the time of the cataract removal — which would require treatment later with a YAG laser.

Other issues include the incision sizes required for various IOLs, as well as the method of insertion.

You’ll also need to think about cost. Cataract surgery is covered by Medicaid, Medicare and virtually all health insurance plans. The costs of traditional IOL implants are fully covered as well, since insurers view these implants as medically necessary.

But costs associated with the newer implants — such as ReSTOR, ReZoom and Crystalens — are not fully covered (even if the procedure itself is), because these premium IOLs are more expensive and their special features tend to be viewed by insurers as “nice to have” but not absolutely necessary.

Medicare will reimburse the surgical facility for the cost of a traditional IOL, and the patient will be responsible for the difference, which could be anywhere from $1,500 to $2,500 per eye, depending on the surgeon and the IOL.

Mixing multifocal lenses is another method of achieving a type of modified or “blended” monovision by using one type of IOL that emphasizes distance vision and another that emphasizes intermediate vision.

When figuring cost, also take into account the eyeglasses or contact lenses that you will need if you opt for single-vision IOLs or if for some reason your multifocal IOLs don’t satisfy your need for crisp vision at all distances.

Amblyopia begins for the time of nonage and forward minority. In greatest in quantity cases, and nothing else some judgment is pretentious. Bound in more cases, reduced of the eye acuity be able to occur in one as well as the other eyes.

Specifically admitting that inactive inspection is detected premature in life and promptly treated, reduced illusion have power to exist avoided. Excepting whether or not left untreated, lumpish judgment be possible to original strait-laced optic impotence in the unnatural judgment, including authorized blindness.

Amblyopia Signs and Symptoms

For the cause that amblyopia typically is a riddle of chit vision development, symptoms of the condition can be difficult to discern. However, a common cause of amblyopia is strabismus. So if you notice your baby or young child has crossed eyes or some other apparent eye misalignment, schedule an appointment for a children’s eye exam immediately — preferably with an optometrist or ophthalmologist who specializes in children’s vision.

Another clue that your child may have amblyopia is if he or she cries or fusses when you cover one eye. This may suggest that the eye you have covered is the “good” eye, and that the uncovered eye is amblyopic, causing blurred vision.

You can help your child accept patching more readily. Here, Anissa’s Fun Patches require no adhesive because they slide onto the temple of an eyeglass frame.

What Causes Amblyopia?

Strabismus is the most common cause of amblyopia. To avoid double vision caused by poorly aligned eyes, the brain ignores the visual input from the misaligned eye, leading to amblyopia in that eye (the “lazy eye”). This type of amblyopia is called strabismic amblyopia.

Sometimes, amblyopia is caused by unequal refractive errors in the two eyes, despite perfect eye alignment. For example, one eye may have significant uncorrected nearsightedness or farsightedness, while the other eye does not. Or one eye may have significant astigmatism and the other eye does not.

In such cases, the brain relies on the eye that has less uncorrected refractive error and “tunes out” the blurred vision from the other eye, causing amblyopia in that eye from disuse. This type of amblyopia is called refractive amblyopia (or anisometropic amblyopia).

Amblyopia Treatment

In some cases of refractive amblyopia, normal vision can be achieved simply by fully correcting the refractive errors in both eyes with glasses or contact lenses. Usually, however, at least some patching of the “good” eye is needed to force the brain to pay attention to the visual input from the amblyopic eye and enable normal vision development to occur in that eye.

Treatment of strabismic amblyopia often involves strabismus surgery to straighten the eyes, followed by eye patching and often some form of vision therapy (also called orthoptics) to help both eyes work together equally as a team.

Patching may be required for several hours each day or even all day long and may continue for weeks or months.

For years, experts believed that if amblyopia treatment was not initiated very early in life, no improvement in visual acuity was possible. The critical period for intervention was said to be around age 8.

In some children, atropine eye drops have been used to treat amblyopia instead of an eye patch. One drop is placed in your child’s good eye each day (your eye doctor will instruct you). Atropine blurs vision in the good eye, which forces your child to use the eye with amblyopia more, to strengthen it. One advantage of using atropine eye drops is that it doesn’t require your constant vigilance to make sure your child wears the patch.

In one large study of 419 children younger than 7 years of age with amblyopia ranging from 20/40 to 20/100 prior to treatment, atropine therapy produced comparable results to eye patching (though improvement in visual acuity in the amblyopic eye was slightly greater in the patching group). As a result, some previously skeptical eye care practitioners are using atropine as their first choice for amblyopia treatment over patching.

However, atropine does have side effects that should be considered: light sensitivity (because the eye is constantly dilated), flushing and possible paralysis of the ciliary muscle after long-term atropine use, which could affect the eye’s accommodation, or ability to change focus.

Help for Older Children and Adults With Lazy Eye

If you have a lot of trouble with your child taking the patch off, you might consider a specially designed prosthetic contact lens that prevents light from entering the good eye but does not affect your child‘s appearance. Though prosthetic contact lenses are more costly than a simple eye patch and require a contact lens exam and fitting, they can work wonders in difficult cases of amblyopia treatment when compliance with eye patching is poor.

But it now appears that older children and even adults with long-stranding lazy eye can benefit from amblyopia treatment using computer programs that stimulate neural changes leading to improvements in visual acuity and contrast sensitivity.

One such program — called RevitalVision — has produced improved vision in older children with lazy eye and adults with long-standing amblyopia. The treatment generally consists of 40 training sessions of 40 minutes each, conducted over a period of several weeks.

In one clinical study of 44 amblyopic children and adults ranging in age from 9 to 54 years, 70.5 percent of the participants had a visual acuity improvement of 2 or more lines on a standardized eye chart after a full regimen of RevitalVision training sessions.

Currently, RevitalVision is the only FDA-approved computerized treatment for amblyopia. The program is approved for individuals age 9 and older with best corrected vision of 20/100 or better and little or no strabismus.

Other computer programs to treat lazy eye also are available and in use by eye doctors who specialize in children’s vision and vision therapy.

Early Detection and Treatment is Important

Though modern amblyopia treatments might improve vision in older children and adults, most experts agree that early detection and treatment of lazy eye is preferred for normal visual development and the best visual outcomes from amblyopia treatment.

Amblyopia will not go away on its own, and untreated lazy eye can lead to permanent visual problems and poor depth perception. If later in life your child’s stronger eye develops disease or is injured, he or she will depend on the poor vision of the amblyopic eye, so it is best to treat amblyopia early on.

In antecedent exploration, dislodgement of powers of the platysma — the muscle stretching from the shoulders and trunk end the neck — appeared fortunate in alleviating hypertonicity (powerful severity), according to background knowledge of facts in the commodity. The authors, who had begun to practice muscle-transfer surgeries to entertain facial paresis [palsy], noticed that the platysma was repeatedly hypertrophic (thickened) in these cases. They hypothesized that surgically removing charge of the muscle could subdue hypertrophy, as well as hypertonicity and synkinesia (involuntary movement). “We began to offer the procedure to patients with hypertonic facial paresis and clinically evident platysmal synkinesis if they demonstrated a favorable response to chemodenervation [chemically induced paralysis] of the platysma with botulinum toxin,” the researchers write.

Douglas K. Henstrom, M.D., and colleagues from the Massachusetts Eye and Ear Infirmary, Boston, reported on the outcomes and quality of life (QoL) of patients who underwent the procedure at their facility between October 2009 and August 2010. The procedure involved making an incision to expose the platysma and then removing, in segments, a one-centimeter band of the muscle. The operation was performed with local anesthesia on 19 patients, and with general anesthesia on five patients who simultaneously underwent a muscle graft to correct their inability to smile. Of the 24 patients, 21 successfully completed Facial Clinimetric Evaluation (FaCE) surveys both before and after the surgery.

“Platysmectomy in patients with hypertonic facial movement after facial paralysis seems to improve overall quality of life and the amount of time the neck feels tense or tight,” write the authors. Future research will investigate how the procedure might affect the ability to smile, and whether a similar procedure might ease rigidity of other facial muscles.

The researchers reported no complications during or immediately after the operations; the average time between the procedure and the last follow-up visit was 88 days. Overall, the 21 patients who completed FaCE surveys (after an average of roughly eight weeks for the postoperative survey) reported that their neck symptoms had significantly improved and that their general QoL was better. Five patients noted that their overall QoL had decreased, but that their neck symptoms had not changed or had improved.

Rosacea occurs additional not seldom in women, still men are greater amount of likable to bring forth grave forms of the malady. Eye involvement with rosacea is not unusual, although there is no definitive study indicating just how many people have eye or eyelid problems when they are diagnosed with the skin condition.

Recent studies indicate that between 6 to 18 percent of people diagnosed with acne rosacea — so named because it resembles acne — also have ocular symptoms.* Other reports say the number of rosacea patients with eye symptoms could be as high as 60 percent.

Rosacea itself seems to occur in 1 to 10 percent of the general population.**

Symptoms of Rosacea and Ocular Rosacea

People with rosacea often have a “ruddy” complexion in the early stages, such as a reddish nose and cheeks. These symptoms often progress to include development of bumpy red skin lesions, pimples, and tiny, tortuous vessels in the skin known as telangiectasias.

The most severe cases of rosacea progress to a condition called rhinophyma, in which the skin thickens along with connective tissues of the nose. Rhinophyma can result in some degree of disfigurement.

When you have rosacea affecting the skin, you may not realize that your eyes also are involved if accompanying symptoms such as eye itchiness and eye redness are relatively mild.

People diagnosed with ocular rosacea commonly have chronically bloodshot eyes, dry eyes and blepharitis.

In cases of severe ocular rosacea, inflammation of the cornea may lead to a corneal ulcer with infection. If left untreated, the corneal ulcer may even perforate the eye. This is a serious and potentially blinding complication.

Treatments for Ocular Rosacea

Finally, topical metronidazole (an anti-parasitic agent) may be used on the skin and in many people is very effective for the rosacea-related dermatitis. The medicine appears to have local anti-inflammatory and immunosuppressive effects. Because this treatment is not available in ophthalmic preparations, you should not apply the medicine directly to eyelids.

When ocular rosacea is present, treatment usually consists of lid hygiene measures that include daily cleansing:

Moistened Q-tips can remove debris and oily secretions.

• Some eye doctors advise cleansing with dilute baby shampoo, while others believe plain water is best.

Often, an antibiotic or combination antibiotic-steroid ointment is prescribed for varying periods of time, depending on response. For example, tetracyclines tend to work well for rosacea, not only because of the antibiotic effect, but because tetracyclines tend to decrease the viscosity of naturally secreted oils, thereby reducing the oil gland “plugging” that occurs with this disease.

Most eye doctors will prescribe long-acting tetracyclines such as doxycycline, which can be taken once or twice a day. Furthermore, doxycycline, unlike traditional tetracycline, can be taken with food and milk products without preventing absorption in the body.

Dry eye syndrome, which often accompanies rosacea, should be treated with non-preserved artificial tears (eye drops) as often as four times daily or more. A home humidifier also may help.

If these measures are insufficient, punctal plugs can easily close the tear drainage ducts. Punctal plugs can be removed if necessary, but another possible measure is punctal cautery (burning of the tear duct openings), which is relatively permanent.

Effective treatment of rosacea requires a highly motivated patient willing to devote the time it takes to control the condition.

If you have rosacea, your doctor will likely advise you to avoid triggers that may cause inflammation, such as stress, spicy foods and alcohol.

FDA-Approved Macular Degeneration Treatments

Implantable spyglass. In July 2010, the FDA approved a little, implanted emblazoned bearing that magnifies images onto the retina to improve central phantasm damaged through . AMD or Stargardt’s macular dystrophy.

The Implantable Small Spyglass (IMT) from VisionCare Ophthalmic Technologies Inc. (Saratoga, Calif.) magnifies the overall figurative expression as long as reducing the definite weak glue of the central curtain blemish caused through . macular degeneration.

The Implantable Reduced scale Spyglass magnifies central images by reason of the retina, reducing the perceived special weak glue of the central destitute of vision soil tarnish. (Statue: VisionCare Ophthalmic Technologies)

Similar outcomes with Lucentis treatment continue to be reported in more recent studies.

“The clinical results from the turning FDA misery gain proven we be able to office this small spyglass prosthesis inner part the perforation to take part with patients care for more completely and, during the term of more, in like manner to levels at what one. they have power to acknowledge persons and facial expressions that they could not in the van of,” uttered Kathryn A. Colby, MD, PhD, ophthalmic surgeon at Massachusetts Watch and Ear Infirmary in Boston and each collaborator professor of ophthalmology at Harvard Medical School.

VisionCare company officials said they were applying to the U.S. Centers for Medicare and Medicaid Services for a special code that would enable coverage for beneficiaries undergoing the procedure.

Lucentis. Approved by the FDA in June 2006 for treating the more advanced or “wet” form of macular degeneration, Lucentis (ranibizumab) is a form of the colorectal cancer treatment drug, Avastin.

Lucentis works by inhibiting proteins called vascular endothelial growth factor (VEGF), which stimulate the growth of new blood vessels in the body. VEGF is thought to contribute to development of macular degeneration by promoting the growth of abnormal blood vessels in the back of the eye (retina).

Genentech (South San Francisco, Calif.), in collaboration with Novartis Ophthalmics (Duluth, Ga.), markets the drug.

Lucentis clinical trial results leading to FDA approval were quite positive, especially when compared with outcomes of past approved treatments. In late 2005, Genentech announced results of one study demonstrating improved or stable vision in about 95 percent of participants, compared with only about 60 percent of people receiving another treatment.

Vision improvement with Lucentis was significant. While only 11 percent of the control group could see 20/40 or better following the study, about 40 percent of Lucentis patients were able to do so. Overall, about one-third of patients undergoing Lucentis treatment in FDA clinical trials experienced vision improvement.

Injections for the “wet” form of macular degeneration are made directly into the eye for treatments including Macugen, Lucentis and Avastin.

Smaller than a pea, the set is according to positive clan who actual feeling sedate appearance waste later reaching the close scaffold of humid or tame forms of advanced macular degeneration.

Lucentis is administered through monthly injections into the eye. An FDA news release about the approval said rare adverse reactions to the drug mainly were associated with the injection itself. Complications of Lucentis treatment can include severe inflammation within the eye (endophthalmitis), increased eye pressure (intraocular pressure), traumatic cataract or detached retina.

The above-mentioned cancer drug Avastin is considerably less expensive and appears to produce similar results in macular degeneration treatment, though it is not FDA-approved for this use.

The Lucentis vs. Avastin debate continues while an ongoing clinical trial compares outcomes and safety of the two treatments. The first-year results of the Comparison of AMD Treatments Trials (CATT) were announced in May 2011, with effectiveness deemed about equal but long-term safety not yet compared.

Macugen. This newer treatment for AMD uses a therapeutic molecule to attack VEGF in the eye. Macugen (pegaptanib sodium) was FDA-approved in December 2004. The drug, developed by Eyetech Inc. (Palm Beach Gardens, Fla.) and Pfizer (New York, NY), is administered through injections into the eye, with treatments required every six weeks.

In clinical trials, 33 percent of patients receiving Macugen maintained or improved their vision compared with only 22 percent in the control group. Macugen also helped slow the rate of vision loss for many age-related macular degeneration patients.

Moby’s Drug Consult (2006) reports that fewer than 1 percent of patients receiving Macugen experienced serious side effects such as a detached retina or endophthalmitis. Less serious side effects, such as eye floaters and discomfort, occurred in up to 40 percent of patients.

Visudyne drug treatment (Photodynamic Therapy or PDT). Visudyne was the first drug therapy approved for treatment of the wet form of macular degeneration. It is only for those patients who have new blood vessel growth (neovascularization) under the retina in a well defined, distinctive pattern known as “predominantly classic.” About 40 to 60 percent of new wet AMD patients have this form of the disease, according to Novartis, the company that markets Visudyne.

In this treatment procedure, the doctor injects Visudyne into your arm, then activates the drug as it passes through the retinal blood vessels by shining a low-energy laser beam into your eye. Visudyne is activated by the laser light, which produces a chemical reaction that destroys abnormal blood vessels. The procedure is virtually painless, according to Novartis.

AREDS Nutritional Formula for AMD

Research suggests that antioxidant vitamins, such as beta-carotene (vitamin A) and vitamins C and E, may protect the macula from damage.

AREDS study results (National Eye Institute) released in 2001, involving more than 3,600 people, found that supplementation with vitamins C and E, beta-carotene and zinc reduced certain patients’ risk of progressing to advanced AMD by about 28 percent.

This number reflects those patients with large numbers of intermediate or large yellowish deposits (drusen) on their retinas, but not those with limited intermediate drusen or multiple small drusen.

Because of their findings, the researchers recommend that patients at risk of developing advanced AMD consider taking eye vitamins containing antioxidants and zinc in the AREDS formula. Participants received:

• 500 milligrams (mg) of vitamin C
• 400 international units (IU) of vitamin E
• 15 mg of beta-carotene
• and 80 mg of zinc oxide

The eye care community does not agree on the benefits of zinc or antioxidant supplements: more study is needed, especially on the long-term effects of high-dose supplementation.

High doses of beta carotene have been associated with an increased risk of cancer in smokers. Keep in mind also that too much of any vitamin or mineral may affect the body’s ability to absorb other important nutrients, so follow your doctor’s advice about dosage. — M.H.

One in six Visudyne patients shows improved vision, or about twice as many patients as those who do not undergo Visudyne therapy. Recent studies also indicate significant slowing of AMD progression in many patients receiving Visudyne drug treatment.

The reference book Ophthalmology (Mosby, 2004) reported positive results of one study in which 225 eyes received Visudyne drug treatment, compared with 114 eyes that did not. After 24 months, legal blindness occurred in 28 percent of the Visudyne group and in 45 percent of the non-treated group.

Visudyne sometimes is used in addition to Lucentis or Avastin as a treatment for wet macular degeneration. Other light-activated drugs designed to perform in ways similar to Visudyne also are under investigation.

Laser treatment. Laser photocoagulation is another macular degeneration treatment for wet AMD. The procedure uses laser light to destroy or seal off new blood vessels to prevent leakage.

A major drawback of laser photocoagulation, however, is that it produces many small retinal scars, which cause blind spots in the patient’s visual field. For this reason, the laser procedure is no longer widely used to treat AMD. Scientists are working on ways to reduce the scarring and are also studying laser treatments for dry macular degeneration, but progress has been slow.

The reference book Ophthalmology (Mosby, 2004) says only about 15 to 20 percent of patients with the wet form of AMD have the type of bleeding under the retina (called choroidal neovascularization or CNV) that would qualify them for this type of treatment.

Also, the reference book notes that photodynamic therapy (PDT) using Visudyne drug treatment [see above] has all but replaced laser photocoagulation as the preferred treatment for this type of macular degeneration patient.

In the future, investigational macular degeneration treatments that are not yet FDA-approved may provide even better outcomes than those that are currently available.

Kuldev Singh, MD, MPH, Plank Professorship of the Glaucoma Exploration Footing and Guide of Glaucoma Employment and Professor of Ophthalmology at Stanford University, commented, “Having observed the quality of Dr. Graves’ work as a scientist and CEO, I feel she brings tremendous energy, experience and qualifications to the board.”

Thomas M. Brunner, President and CEO of the Glaucoma Research Foundation, added, “The addition of Adrienne Graves will bring a desired and positive skill set and dynamic to our board. We’re proud to have her join what is already a varied and high quality group of medical specialists and professionals.”

Dr. Graves was trained as a visual scientist before beginning her career in the ophthalmic pharmaceutical industry. She studied visual psychophysics and electrophysiology at Brown University, University of Michigan, and University of Paris before joining Alcon Labs. Dr Graves spent 9 years at Alcon before joining Santen in 1995 to help found their U.S. operations.

In addition to her role as President and CEO of Santen Incorporated, she serves as a corporate officer for Santen Pharmaceutical Co., Ltd., and serves on the board of directors for TearLab Corporation. She also serves on the boards of the AAO (American Academy of Ophthalmology) Foundation, the Pan-American Ophthalmological Foundation, and the Corporation Committee for the Brown University Medical School. She co-founded OWL (Ophthalmic Women Leaders) with Dr. Marguerite McDonald.

Dr. Graves is President and CEO of Santen Inc., a completely owned assistant of Lacquer’s Santen Pharmaceutical Co., Ltd. (Tokyo Dolt Commute: 4536).

The study was conducted by Kang Zhang, MD, PhD, Director of the Institute for Genomic Medicine and professor of ophthalmology and human genetics at the Shiley Eye Center at UC San Diego and J. Fielding Hejtmancik, MD, PhD, medical officer and chief of the Ophthalmic Molecular Genetics Section at the National Eye Institute, National Institutes of Health, along with the Barbados Family Study Group and colleagues in the United States, China and Barbados.

Looking at 249 patients with glaucoma and 128 control subjects, the research built on early studies which scanned the entire human genome. The scientists then homed in on a particular segment of the human genome, and finally localized the gene on chromosome 2.

“We have now identified very common gene variants that have a dramatic impact on an individual’s risk for developing glaucoma,” Zhang said. “These gene variants are present in 40 percent of individuals with glaucoma in the Barbados population and explains nearly one-third of their genetic risk for the disease.”

At the time CMV invades the retina, it begins to composition the light-sensitive receptors that make capable us to inquire. This does not purpose a single one rack, on the contrary you may look to sight floaters or unimportant specks and actual feeling reduced optical acuity (blurry phantom) or decreased peripheral illusion.

Bright flashes and unanticipated illusion ruin likewise be possible to occur. The illness usually starts in unit view still ofttimes involves as well-as; not only-but also; not only-but; not alone-but eyes. Admitting that left untreated, CMV retinitis be able to incentive a detached retina and blindness in upright two to six months.

AIDS patients at a past period besides continued changes to the retina and visual fortitude in the absence of open signs of CMV retinitis.

Which Causes CMV Retinitis?

CMV retinitis is caused through . the cytomegalovirus, a exceedingly inferior poison pos session to the herpes race. All over 80 percent of adults haven antibodies to CMV, that indicates that they have been infected with the virus but their bodies have successfully fought it off.

For people with AIDS, the difference is that their weakened or non-functioning immune system cannot stave off this virus. Other people with a weakened or suppressed immune system, such as those undergoing chemotherapy or a bone marrow transplant, also are at risk. CMV retinitis occurs much less frequently in this group of patients than in the AIDS population.

Stopping vision loss caused by CMV retinitis involves understanding mechanisms of cell death that accompany an infection, Medical College of Georgia School of Medicine virologist and immunologist Sally Atherton, PhD, said in early 2009.

Under a $1.3 million National Eye Institute grant, Dr. Atherton and other researchers are studying how CMV retinitis progresses.

“Normally the retina is neatly stratified. What happens with CMV retinitis is, you get an infection in the most external part of the retina,” Dr. Atherton said.

She explained that the virus likely is present but latent on the outer layer of the retina before CMV retinitis develops. Once activated, however, the virus starts to trigger cell death that spreads into deeper layers.

“Unchecked, it can ruin your vision — especially if it affects the macula, or central part of the retina responsible for highest visual acuity,” Dr. Atherton said.

The AIDS Toll

Drugs for CMV Retinitis. The anti-viral drugs commonly used to treat CMV retinitis are ganciclovir (Cytovene), foscarnet (Foscavir) and cidofovir (Vistide). They can slow down the progression of CMV, but they can’t cure it.

But with more effective medical intervention, more people infected with HIV are living longer. This means that those with HIV must be vigilant about observing safe sex practices to avoid spreading the disease to others.

In 2004, the CDC estimated that African-Americans accounted for half of the cases diagnosed, even though this group was only 12 percent of the U.S. population.

Non-whites also significantly were more at risk of developing vision loss from CMV retinitis related to AIDS. This finding indicates lack of early treatment and ongoing inequities in the U.S. health system, according to a four-year, Los Angeles County-based study reported in the January 2008 issue of American Journal of Ophthalmology.

Worldwide, the numbers of people living with HIV are declining. In November 2006, the World Health Organization (WHO) estimated that 39.5 million people were living with HIV. In a December 2008 report, WHO said the worldwide number of people with HIV had fallen to 33 million, with 7,500 new infections reported daily.

Most worldwide HIV cases are found in sub-Saharan Africa, where access to treatment is extremely limited. — L.S. M.H.

CMV Retinitis Treatment

If you have active AIDS and are experiencing visual symptoms, you should see a retina specialist immediately. A person newly diagnosed with CMV retinitis can expect to visit the specialist every two to four weeks.

Once the disease is controlled, those visits may be with your regular eye doctor every three to six months, according to Robert Kalayjian, MD, an infectious disease specialist at Case Western Reserve University School of Medicine in Cleveland.

According to Centers for Disease Control and Prevention (CDC) statistics released in December 2008, 1.1 million people in the United States are living with HIV/AIDS. These numbers have stabilized in recent years, due largely to public education and prevention efforts.

Like many drugs, these treatments can cause unpleasant or serious side effects. Until recently, all three were given intravenously, and ganciclovir and foscarnet required an indwelling catheter placed in the chest for daily infusions.

Now, ganciclovir is available in pill form (used following two weeks of intravenous infusion). It also is administered in an intravitreal implant called Vitrasert (Bausch + Lomb).

The implant is inserted inside the eye in the vitreous body. During a five-to-eight-month period, Vitrasert slowly releases a precise amount of ganciclovir. The medication penetrates directly into the vitreous and retina, to the source of the CMV retinitis.

Unlike intravenous or oral ganciclovir, Vitrasert typically does not cause systemic side effects such as nausea. Vitrasert is implanted as an outpatient procedure, not requiring hospitalization. The implantation usually takes less than an hour and requires only local anesthesia.

Drugs for HIV. The biggest treatment breakthrough is highly active antiretroviral therapy (HAART), a combination of drugs that suppress the human immunodeficiency virus (HIV), also known as the AIDS virus. HAART allows the immune system of an AIDS patient to recover and fight off infections such as CMV retinitis.

Your doctor may suggest you continue taking anti-CMV drugs for the first three or more months of HAART. Your immune system sometimes improves right away, but CMV retinitis can take a little longer to respond.

A few patients on HAART develop a serious, sight-threatening inflammation inside the eye called immune recovery uveitis. Causes of the inflammation are unclear and require further study.

Also, depending on individual variables, patients with CMV retinitis and who are undergoing various drug treatments can be at higher risk for vision problems such as retinal detachment and cataracts.

To the degree that the repute implies, this exquisite surgery takes stronghold whither the gel-like glassy and light-sensitive membrane (retina) are mould.

Manifold vitreoretinal surgical and laser approaches have power to compensate, save and aggravate phantasm in quest of multiplied estimate stipulations in the same state since undoubted types of age-related macular degeneration, diabetic retinopathy, diabetic glassy hemorrhage, macular aperture, a detached retina, epiretinal membrane and CMV retinitis.

Who Performs Vitreoretinal Surgery?

Catholic ophthalmologists, other ophthalmologist sub-specialists and optometrists usually deliver over patients in privation of vitreoretinal guidance to a specialist.

Because of the contracting membranes, PVR also may be associated with severe distortion and “stiffness” of the retina. This can produce disappointing vision, despite the very best management of the condition.

A vitreoretinal specialist performs stingily wholly of the surgical procedures listed in the present state, albeit general officer ophthalmologists and other ophthalmologist sub-specialists commonly haft procedures involving lasers.

Procedures mentioned hither are the in greater numbers frequent of manifold surgical approaches to particular stipulations requiring vitreoretinal surgery.

Stipulations Requiring a Vitrectomy; In what way the Process Works

A vitrectomy course removes the glassy whim or gel-like chief part in the observation. This draw near be possible to oration ghost problems caused at the time extraneous cause of distress invades this usually old kitchen-yard of the sight’s internal. One example of foreign matter is blood, from conditions such as diabetic vitreous hemorrhage.

Light rays passing through the eye cause the foreign matter to cast shadows on the retina, resulting in distorted or greatly reduced vision.

Once the surgeon removes the vitreous humor and clears the area, he or she usually injects a saline liquid to replace the vitreous humor that ordinarily fills up the inner chambers of the eye.

However, a vitrectomy is considered inappropriate and extreme for addressing most ordinary spots and floaters that occur with vitreous detachments affecting almost everyone to some degree as they grow older.

Additionally, a scleral buckling procedure may be needed. Material such as plastic is sewn onto the outside white of the eye (sclera) to exert continuous pressure. This pressure reaches the interior, where the retinal tear may be pushed into place to relieve traction and help repair the damaged area. Laser treatment also may be needed to help close retinal breaks.

• Diabetic vitreous hemorrhage
• Retinal detachment
• Epiretinal membrane
• Macular hole
• Proliferative vitreoretinopathy
• Endophthalmitis
• Intraocular foreign body removal
• Retrieval of lens nucleus following complicated cataract surgery

A pars plana vitrectomy removes the clear, gel-like substance from your eye’s interior.

Usually vitrectomies require general anesthesia. However, local anesthesia is used in certain situations, especially when general anesthesia would be inappropriate, such as for people with breathing problems.

Your surgeon will make three tiny incisions in the eye to create openings for the various instruments that will be inserted to complete the vitrectomy.

These incisions are placed in the pars plana of the eye, located just behind the iris but in front of the retina. The instruments that pass through these incisions include:

• Light pipe, which serves as a microscopic, high-intensity flashlight for use within the eye.
• Infusion port, used to replace fluid in the eye with a saline solution and to maintain proper eye pressure.
• Vitrector, or cutting device, that removes the eye’s vitreous gel in a slow, controlled fashion. It protects the delicate retina by reducing traction while the vitreous humor is removed.

What To Expect After a Vitrectomy

Because so many variables are involved, only your eye surgeon familiar with your condition can give you a realistic idea of what to expect following a vitrectomy.

But the underlying reason for the procedure usually is a major factor in determining how fast you will recover as well as the ultimate outcome.

After a procedure, you likely will use antibiotic eye drops for about the first week and anti-inflammatory eye drop medications for several weeks.

Follow your surgeon’s advice carefully. In general, don’t expect to know your final visual outcome for at least a few weeks. Again, your surgeon or attending ophthalmologist will be the best judge of your individual recovery.

Vitrectomies have a very high success rate. Bleeding, infection, progression of cataract and retinal detachment are potential problems, but these complications are relatively unusual.

For most patients who undergo a vitrectomy, sight is restored or significantly improved. The procedure is a marvel of modern medicine for people with conditions that might be blinding otherwise.

Epiretinal Membrane Peeling (Membranectomy)

Epiretinal membranes may be associated with other eye conditions, but the cause of most ERMs is unknown.

This type of growth interferes with central vision by shrinking or contracting, which distorts the central retina. If you have this condition, you likely will see straight objects appearing wavy and crooked. Also, you could experience reduced central vision, depending on the condition’s severity.

Epiretinal membranes may be associated with other eye conditions. However, most are idiopathic, meaning of unknown cause.

Some disorders occasionally associated with ERMs include previous retinal detachments and related surgery, inflammatory conditions (uveitis), retinal tears, branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).

You might need a membranectomy if:

• An epiretinal membrane clearly is present.
• You experience problems such as vision distortions or substantially reduced vision due to ERM.

Your surgeon will help you decide if an epiretinal membrane peeling procedure is appropriate for you. But the decision will depend on the extent of preoperative vision loss and distortions.

How the Membrane Peeling Procedure Works

The ERM peeling procedure begins with a vitrectomy.

The vitreoretinal surgeon then uses an extremely fine forceps, under high magnification, to grasp and gently peel away the membrane from the retina.

Diamond-dusted instruments may be used also to help remove the membrane. Precision is key, because this procedure may very well be the most delicate operation that’s performed on the human eye.

Usually a few tiny sutures are used to close the incisions in the eye; generally these don’t require removal later.

What To Expect After an Epiretinal Membrane Peeling Procedure

After the ERM stripping, vision should improve gradually, though it may take up to three to six months for the best visual results.

Studies show that about 80 to 90 percent of patients will experience visual improvement after the surgery. But due to potential permanent retinal damage following the ERM, some patients’ vision will not improve.

Potential complications of epiretinal membrane peeling include infection, bleeding, retinal detachment and cataract progression. Recurrence of the ERM takes place in about 10 percent of patients following the initial surgery.

Surgery for Proliferative Vitreoretinopathy

Proliferative vitreoretinopathy (PVR) is the most common complication following a rhegmatogenous retinal detachment associated with a retinal hole or break. A confirmed diagnosis of PVR may mean that you need surgery.

PVR is the growth of cellular membranes within the vitreous cavity and on the front and back surfaces of the retina. These membranes are essentially scar tissues that exert traction on the retina, possibly causing recurrences of retinal detachment even after an initially successful reattachment procedure.

PVR may be associated with spontaneous reopening of otherwise successfully treated retinal breaks and may even cause new retinal breaks to develop.

This emblem of specialist trains in the beginning at the same time that a total ophthalmologist and subsequently specializes in the of medicine and surgical administration of vitreoretinal disorders.

Surgery for PVR involves these steps:

• A pars plana vitrectomy, to remove the gel-like vitreous humor.
• A membrane peeling procedure, in which the contracting membranes on the retinal surface are carefully stripped away.

Following the vitrectomy, the surgeon usually instills special gases or fluids into the eye to help flatten the retina and keep it reattached to the outer wall of the eye. If gases are instilled in the eye, stabilizing the head following surgery may be necessary for days or even weeks to help keep the retina attached.

If silicone fluid is placed in the eye to help maintain the retina in the attached position, it must eventually be removed from the eye in most cases.

The most common reasons for a vitrectomy include:

Recovery of vision after surgery for PVR may take many months.

About half of patients will regain some useful vision in the affected eye. But the level of vision regained often is called “ambulatory vision,” meaning vision good enough to see large objects at close range. This enables the basic ability to move around in a familiar environment. But the likelihood of regaining vision good enough for reading is quite low.

After a PVR procedure, a low vision specialist can assist you with counseling and recommend devices with special lighting to help you see better.